Vile R - Search Results

1

Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas.

Galanis E, Bateman A, Johnson K, Diaz RM, James CD, Vile R, Russell SJ. Galanis E, et al. Among authors: vile r. Hum Gene Ther. 2001 May 1;12(7):811-21. doi: 10.1089/104303401750148766. Hum Gene Ther. 2001. PMID: 11339897

2

Gene transfer technologies for the gene therapy of cancer.

Vile R, Russell SJ. Vile R, et al. Gene Ther. 1994 Mar;1(2):88-98. Gene Ther. 1994. PMID: 7584073 Review.

3

Retroviruses as vectors.

Vile RG, Russell SJ. Vile RG, et al. Br Med Bull. 1995 Jan;51(1):12-30. doi: 10.1093/oxfordjournals.bmb.a072941. Br Med Bull. 1995. PMID: 7767638 Review.

4

Tissue-specific gene expression from Mo-MLV retroviral vectors with hybrid LTRs containing the murine tyrosinase enhancer/promoter.

Vile RG, Diaz RM, Miller N, Mitchell S, Tuszyanski A, Russell SJ. Vile RG, et al. Virology. 1995 Dec 1;214(1):307-13. doi: 10.1006/viro.1995.9923. Virology. 1995. PMID: 8525635 Free article.

5

Targeted gene therapy for cancer: herpes simplex virus thymidine kinase gene-mediated cell killing leads to anti-tumour immunity that can be augmented by co-expression of cytokines in the tumour cells.

Vile RG, Diaz RM, Castleden S, Chong H. Vile RG, et al. Biochem Soc Trans. 1997 May;25(2):717-22. doi: 10.1042/bst0250717. Biochem Soc Trans. 1997. PMID: 9191190 Review. No abstract available.

6

Euro targeting in Leiden: the fourth meeting of the EWGT, University of Leiden, 14-17 November 1996.

Diaz RM, Vile R. Diaz RM, et al. Among authors: vile r. Gene Ther. 1997 Jun;4(6):501-3. doi: 10.1038/sj.gt.3300445. Gene Ther. 1997. PMID: 9231064 No abstract available.

7

A family of bicistronic vectors to enhance both local and systemic antitumor effects of HSVtk or cytokine expression in a murine melanoma model.

Castleden SA, Chong H, Garcia-Ribas I, Melcher AA, Hutchinson G, Roberts B, Hart IR, Vile RG. Castleden SA, et al. Among authors: vile rg. Hum Gene Ther. 1997 Nov 20;8(17):2087-102. doi: 10.1089/hum.1997.8.17-2087. Hum Gene Ther. 1997. PMID: 9414257

8

Exchange of viral promoter/enhancer elements with heterologous regulatory sequences generates targeted hybrid long terminal repeat vectors for gene therapy of melanoma.

Diaz RM, Eisen T, Hart IR, Vile RG. Diaz RM, et al. Among authors: vile rg. J Virol. 1998 Jan;72(1):789-95. doi: 10.1128/JVI.72.1.789-795.1998. J Virol. 1998. PMID: 9420288 Free PMC article.

9

Strategies for achieving multiple layers of selectivity in gene therapy.

Vile RG, Sunassee K, Diaz RM. Vile RG, et al. Mol Med Today. 1998 Feb;4(2):84-92. doi: 10.1016/S1357-4310(97)01157-X. Mol Med Today. 1998. PMID: 9547795 Review.

10

Rapid adenoviral transduction of freshly resected tumour explants with therapeutically useful genes provides a rationale for genetic immunotherapy for colorectal cancer.

Diaz RM, Todryk S, Chong H, Hart IR, Sikora K, Dorudi S, Vile RG. Diaz RM, et al. Among authors: vile rg. Gene Ther. 1998 Jul;5(7):869-79. doi: 10.1038/sj.gt.3300690. Gene Ther. 1998. PMID: 9813657

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

312 results

Search Page

Filters